Who are Irinotecan Liposomal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Camptosar, Idamycin Pfs, Idamycin Pfs, Idamycin Pfs, Cipro, Amekrin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irinotecan-liposomal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Irinotecan Liposomal — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irinotecan Liposomal (Irinotecan Liposomal) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase I inhibitor. Area: Oncology.

phase 3 Topoisomerase I inhibitor Topoisomerase I Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Irinotecan Liposomal (Irinotecan Liposomal) — The First Affiliated Hospital of Zhengzhou University. Irinotecan liposomal is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA religation during replication, leading to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Irinotecan Liposomal TARGET	Irinotecan Liposomal	The First Affiliated Hospital of Zhengzhou University	phase 3	Topoisomerase I inhibitor	Topoisomerase I
Camptosar	irinotecan	Pfizer	marketed	Topoisomerase Inhibitor	topoisomerase I	1996-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Amekrin	AMSACRINE		marketed	amsacrine	DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Topoisomerase I inhibitor class)

Accelerated Community Oncology Research Network · 1 drug in this class
Amgen · 1 drug in this class
Cancer Advances Inc. · 1 drug in this class
Chinese Academy of Medical Sciences · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
Epidemiological and Clinical Research Information Network · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
St. Jude Children's Research Hospital · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irinotecan Liposomal — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-liposomal. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing